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GLOSSARY OF TERMS AND ACRONYMS 
ALT - alanine aminotransferase, an enzyme produced inside liver cells that may be 
elevated in people with HCV, indicating possible liver damage; detectable in blood tests. 
AST - aspartate aminotransferase, another enzyme produced in the liver; elevated levels 
may indicate liver damage, or other organ or muscle damage. 
Ascites- abnormal buildup of abdominal fluid; a complication ofliver disease. 
Average annual growth rate- the simple mean of a series of year-on-year growth rates 
for a quantity observed annually over a time period spanning two or more years. 
(Example: A stock price is $100 in 2000, $110 in 2001, and $132 in 2002. This 
represents 1 0% growth in the first year and 20% growth in the second year, so the 
average annual growth rate is (10% + 20%) /2, or 15%.) 
CAGR- Compound Annual Growth Rate- another method of calculating "average" 
annual growth rates for time series data. CAGR is the annual growth rate that, if applied 
each year over the time period observed, beginning with the quantity observed for the 
first year, would yield the quantity observed in the last year. In this paper, CAGR is 
calculated using the simple formula: 
(last year quantity/first year quantity) (1/(lengthoftimeperiod))- 1. Using the example above, 
the CAGR would be: (132/100) (1/2) -1, or 14.9%. Note that in this example and in many 
real time series, the average annual growth rate and the CAGR are similar. 
CDC- Centers for Disease Control and Prevention. 
Cirrhosis -liver damage in which normal liver cells are replaced with scar tissue, blood 
flow is restricted, and the liver begins to lose function. 
Compensated cirrhosis- cirrhosis in which the liver is damaged, but still functioning. 
Decompensated cirrhosis- cirrhosis in which the liver is severely impaired, usually 
treatable only by liver transplantation. 
Fibrosis- scarring of the liver, occurring in progressive stages and often leading to 
cirrhosis. 
HA V- Hepatitis A virus. 
HBV- Hepatitis B virus. 
HCC- Hepatocellular carcinoma (liver cancer). 
HCUP- Healthcare Cost and Utilization Project. 
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HCV- Hepatitis C virus. 
ICD-9-CM- International Classification of Diseases, Ninth Revision, Clinical 
Modification. The official system of assigning codes to diagnoses and procedures 
associated with hospital utilization in the United States. 
ICD-1 0- International Classification of Diseases, Tenth Revision. The coding system 
used for classification of mortality statistics in the United States and internationally. 
NHANES- National Health and Nutrition Examination Survey. 
Nosocomial- acquired in a hospital setting. 
RIBA- recombinant immunoblot assay; a blood test to detect antibodies. 
RNA -ribonucleic acid, the genetic material of a virus; RNA blood tests detect presence 
of actual virus, not just antibodies, in the blood. 
Schistosomiasis - a parasitic infection acquired from freshwater sources, in which worms 
invade the host and release eggs that cause damage to the liver and other organs; 
prevalent in parts of Africa, South America and other regions. 
s/co ratios- signal-to-cutoff ratios, used to improve the predictive value of screening 
tests; an s/co value can be identified, for each type of antibody test, that would predict a 
true anti-HCV-positive test result at least 95% of the time, regardless of the anti-HCV 
prevalence or other characteristics of the population being tested. 
SVR- sustained virological response; indicates that HCV RNA is undetectable in the 
blood for at least six months following a prescribed course of treatment. 
WHO- World Health Organization. 
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ABSTRACT 
Chronic infection with the hepatitis C virus (HCV) is recognized as a rapidly 
growing global, national, and local public health problem. More than 3 million people in 
the United States, and 130 million people worldwide, are living with chronic HCV 
infection. Chronic HCV can progress to serious, debilitating forms ofliver disease, 
including advanced cirrhosis and liver cancer. Available treatments for HCV are 
expensive and not always effective, and there is no vaccine to prevent HCV. Published 
mathematical models and data analyses have predicted and documented dramatic growth 
in the number of patients in the United States with advanced disease related to HCV, with 
corresponding increases in hospitalizations and medical costs. However, these analyses 
used data only through 2001, and were not conducted at the state (North Carolina) level. 
The objective of this paper is to summarize the current state of knowledge about HCV in 
North Carolina, with an emphasis on the impact or burden of the disease. With this 
assessment as a base, the paper identifies areas for further research and policy change. 
Available state-level epidemiologic data, hospital utilization data, and Medicaid 
claims data were analyzed to investigate the recent and current impact of HCV in North 
Carolina. Trends in HCV -associated hospital stays and charges were measured by patient 
age group, gender, and payer. Long-term (1996-2004) growth rates in hospital stays and 
charges attributable to HCV were observed to be approximately 20% per year, with 
significant variation by age group. These high rates of growth are not explained by 
overall North Carolina hospital utilization trends, which demonstrate much smaller 
growth rates over the same time periods. The majority ofHCV-related hospital stays and 
charges are experienced by males overall, and by both males and females aged 35-54. 
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However, the highest annual growth rates in stays and charges are now seen in the 55-64 
age group, reflecting the aging of the population chronically infected with HCV and the 
gradual progression ofHCV infection to severe forms of liver disease. North Carolina 
hospital charges attributable to HCV were over $70 million in 2004 (2005 dollars); 
charges could easily be over $100 million in 2006 if current trends continue. The North 
Carolina Medicaid program has also experienced growth in the number of recipients with 
an HCV diagnosis, and associated paid claims amounts, from 2003 through 2005. The 
number of annual deaths associated with hospital stays for HCV in North Carolina has 
grown significantly over the past several years. These findings suggest that there is a 
need for the morbidity, mortality, and societal costs associated with HCV to be more 
effectively addressed and controlled in North Carolina. 
Policy changes are recommended based on the burden ofHCV disease and the 
lack of public health capacity to address HCV in North Carolina. Free or low-cost HCV 
screening is generally not available in public health clinics or similar settings, and is 
needed in order to identity, counsel, and treat HCV patients at risk for serious liver-
related disease. In addition, improved surveillance systems and an HCV patient registry 
would help to monitor patient progress over time, inform interventions, and improve 
outcomes. Additional research is needed to identifY the regions of North Carolina most 
in need of access to HCV testing and treatment, and also to identity the locations and 
populations in which testing programs may be most cost-effective and successful. 
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1. INTRODUCTION 
Chronic infection with the hepatitis C virus (HCV) is recognized as a growing 
public health problem globally, nationally, and in many individual states. Chronic HCV 
is a communicable, blood-borne disease that can progress over time, eventually causing 
cirrhosis, liver cancer, other forms of debilitating liver disease, and death. Chronic HCV 
is recognized as a major cause of liver transplants in the United States. Prevalence of 
positive antibodies, indicating past or present HCV infection in the U.S. population, was 
recently estimated at 1.6% of the population (4.1 million people), with 1.3% (3.2 million 
people) having chronic infection. 1•2 
Acute HCV infection is an illness of limited duration which can occur following 
initial exposure to HCV. Acute HCV is a reportable disease in North Carolina, whereas 
chronic HCV infection is not. Because of improvements in awareness and prevention of 
transmission, the incidence of new (acute) HCV infections has declined dramatically in 
the United States. 3 However, because as many as 85% of acute infections progress to 
chronic infection, long-term chronic HCV disease continues to affect people who 
acquired the infection decades ago. The shortage of state-level data on chronic HCV 
infection makes it challenging to assess the current and future impact of the disease, 
assess public health and health care needs for the disease, develop policies, and plan state 
and local programs for education, prevention, and testing of high-risk populations. In 
North Carolina and in many other states, funding is extremely scarce for state and local 
interventions to prevent new cases ofHCV, and even more importantly, to identifY and 
treat chronically infected patients. 
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Long-term chronic HCV disease now represents a growing, significant global 
health challenge. Published mathematical models ofHCV disease progression and 
analyses of available data4-7 have predicted and documented dramatic increases in the 
number of patients with advanced liver disease related to HCV with corresponding 
increases in hospitalizations and direct medical costs. Available treatments to limit or 
prevent HCV disease progression are expensive, can cause significant side effects, and 
have limited effectiveness in many patient subgroups. In contrast to hepatitis A and B 
(HA V and HBV), no vaccine is currently available for HCV. 
Published analyses and models that measure the costs ofHCV 4-7 are not current 
and do not provide estimates specific to individual states such as North Carolina. 
Therefore, there is a need for current, state-specific analyses of available data on HCV 
disease-related costs. In light of this situation, the North Carolina Hepatitis C Program, 
Division of Public Health, began an initiative to quantitatively assess the human and 
economic impact ofHCV disease in North Carolina. The analysis presented in this paper 
was conducted at the request of the North Carolina Hepatitis C Coordinator and the North 
Carolina Viral Hepatitis Task Force. The results of this analysis will be reported to the 
North Carolina Viral Hepatitis Task Force, the North Carolina State Center for Health 
Statistics, and other state government officials. 
1.1: Goals and Objectives. The overall goal of this paper is to quantify the 
current impact, or disease burden, of chronic HCV in North Carolina. However, this 
paper is not a formal economic burden-of-illness study. The burden of an illness can be 
measured in a number of ways, using a variety of measures ranging from simple 
epidemiologic indicators (such as incidence, prevalence, and mortality rates), to complex 
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economic analyses of direct and indirect medical costs. Comprehensive burden-of-illness 
studies often measure impacts in quality-adjusted life years (QALYs) or disability-
adjusted life years (DALY s), which are used in formal cost-effectiveness analyses and to 
inform global resource allocation decisions. For the purpose of this research, the state-
level impact (or burden) ofHCV will be measured in terms of the available 
epidemiologic data (including prevalence, mortality, and liver transplant data), hospital 
utilization data (including hospital stays and charges), and state Medicaid claims 
statistics. Results will be reported in terms that should be familiar and relevant to state 
and local-level health authorities and policymakers, such as total hospital stays, average 
hospital charges, and average growth rates over time periods. The terms "impact" and 
"burden" will be used interchangeably to refer to the specific human and economic 
effects ofHCV disease that are addressed in this paper. 
In brief, the objectives of this paper are: 
I) To review the global and national epidemiology of chronic HCV, including 
prevalence (proportion of the population chronically infected), transmission and 
risk factors, and testing and treatment issues; 
2) To summarize available information on the epidemiology ofHCV in North 
Carolina, including mortality and liver transplant data, and compare this 
information with national-level data; 
3) To describe previous studies that sought to quantifY the costs ofHCV nationally; 
4) To quantifY the human and economic impact ofHCV in North Carolina using 
available data on inpatient hospital utilization and Medicaid claims data; 
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5) To measure trends in North Carolina HCV-related hospital utilization from 1996 
through 2004; 
6) To describe the current status of free HCV testing programs in North Carolina; 
7) To recommend directions for further research and policy change. 
Toward these goals, the next three sections of this paper briefly summarize the 
epidemiology of chronic HCV infection from global, national, and North Carolina 
perspectives. The fifth section reviews previously published national-level estimates of 
the current and future medical and other costs associated with HCV. The sixth section of 
this paper presents an analysis ofHCV-related inpatient hospital stays and charges based 
on the North Carolina Hospital Discharge Database, and also reports current statistics on 
the costs ofHCV to the state Medicaid program. The paper concludes with a summary of 
the status of free HCV screening programs in North Carolina and related policy issues, 
and recommends steps for further data collection, research, and policy. 
2. GLOBAL EPIDEMIOLOGY OF CHRONIC HEPATITIS C INFECTION 
2.1: Prevalence by Region. Estimates of global HCV prevalence vary. The 
World Health Organization estimates that 130 million persons around the world (2% of 
the global population) are chronically infected with HCV, with 3 to 4 million new 
infections occurring per year.8 Estimates of prevalence ofHCV in individual countries 
and communities also vary widely, and typically rely upon cross-sectional seroprevalence 
studies of convenient populations (such as blood donors) that may not adequately 
represent the target population9 Based on the limited information available, WHO 
occasionally reports data on the prevalence ofHCV infection by country and region. In 
2001, WHO estimated HCV prevalence greater than 10% in Bolivia, Mongolia, 
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Cameroon, Guinea, and Egypt, and prevalence between 2.5 and 10% in several countries 
in Asia (including China and Japan) and Africa, as well as in Ukraine, Romania, and 
Brazil. 10 In North America and in most of Europe, India, and Australia, WHO estimated 
HCV prevalence to be 1% to 2.5%. 10 Prevalence estimates are constantly changing as 
new studies are regularly published in specific populations within each region. 
2.2: Transmission and Risk Factors. Because HCV is transmitted through 
human blood contact, the major causes ofHCV infection worldwide are transfusions 
from unsafe blood supplies, shared needles and drug paraphernalia associated with 
injection drug use, and re-use of needles and syringes in health care and other settings.9•11 
Less commonly, transmission may also occur through sexual and perinatal exposures. 
Other modes of transmission may include religious and cultural practices such as ear and 
body piercing, circumcision, and tattooing with unsterilized equipment, although data are 
insufficient to conclude that these are significant. 9 Unlike hepatitis A (HA V), HCV is not 
food-borne. HCV is not spread by sneezing, coughing, or casual contact. 
In high-income countries such as the United States, Australia, and several 
countries in Europe, HCV is not highly communicable in most populations. There is 
strong evidence to conclude that behaviors associated with injection drug use are the 
primary source of new HCV infections. However, in low- and middle-income 
(developing) countries, unscreened blood transfusions and unsafe therapeutic injections 
are important.9 Efforts are underway to improve screening of blood products in 
developing countries and to improve injection practices in medical settings. 
Egypt provides a sobering example of the potential impact of unsafe therapeutic 
injections on the transmission ofHCV. Seroprevalence ofHCV antibodies in Egypt is 
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15%-20%, the highest in the world. HCV was widely transmitted during the anti-
schistosomiasis campaigns that were undertaken from the 1950s through the 1980s using 
contaminated injection equipment. 12•13 Ironically, schistosomiasis was the major cause of 
liver disease in Egypt prior to the 1990s, but HCV is now the predominant cause. An 
estimated 6 million Egyptians are now chronically infected with HCV, which presents a 
huge challenge to Egyptian health authorities. Few Egyptian patients have access to 
chronic HCV treatment. 13 
2.3: Co-infection with HIV and Comparisons with HBV. The global 
epidemiology ofHCV is best understood in the context of two other important causes of 
death from infectious disease: human immunodeficiency virus (HIV) and hepatitis B 
virus (HBV). All three diseases are blood-borne with shared routes of transmission and 
risk factors, such as injection drug use or exposure to un-sterilized needles and other 
medical equipment. Although vaccines to prevent HBV have been available for more 
than 20 years, chronic HBV is much more easily transmitted than HCV or HIV and is 
still far more prevalent than HCV worldwide; an estimated 350 million people are 
chronically infected with HBV. 14 HIV is far less prevalent than HCV, as there are an 
estimated 39 million people living with HIV/ AIDS. 15 About 4 to 5 million people are 
estimated to be co-infected with HCV and HIV, whereas 2 to 4 million are estimated to 
be co-infected with HBV and HIV. HCV infection has been found in 25-30% ofHIV-
positive individuals, and in 72-95% ofHIV-positive injection drug users. 16 Estimates of 
co-infection rates vary substantially by country and by risk group. 
HCV behaves as an opportunistic infection in HIV-positive patients. Although 
the disease progression of both HIV and HCV in co-infected people is a subject of 
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debate, there is evidence suggesting that end-stage liver disease is now a major cause of 
death in these patients.9•17 HIV infection is known to lead to faster progression ofHCV-
related liver diseases such as cirrhosis. 17 
2.4: Priority of HCV in Global Health. Unfortunately, no vaccine is yet 
available to prevent HCV, and the cost of available treatments for chronic HCV is 
prohibitively high for developing countries. Compared with low-cost, highly effective 
interventions such as childhood immunization and malaria prevention, HCV is given low 
priority. Interventions to delay HCV disease progression appear to be uncommon in 
developing countries. However, HCV transmission could be reduced as a result of cost-
effective interventions such as blood and needle safety programs, which are now 
primarily used to prevent HIV transmission. A recent report of the Disease Control 
Priorities Project (DCPP) ranked these programs high on a list of cost-effective global 
health interventions; prevention of alcohol misuse (which could help delay HCV 
progression) was also listed as cost-effective. 18 Until an HCV vaccine is available and/or 
treatments to prevent disease progression are cheaper and widely available, global 
interventions targeting HCV will probably remain scarce. 
3. EPIDEMIOLOGY OF CHRONIC HEPATITIS C INFECTION IN THE 
UNITED STATES 
3.1: Chronic HCV Prevalence in the United States. Using antibody (anti-
HCV) tests on serum samples from the third National Health and Nutrition Examination 
Survey (NHANES III), conducted from 1988 through 1994, investigators determined that 
the overall prevalence of exposure to HCV in the United States was approximately 1.8 
percent. This widely quoted estimate corresponded to 3.9 million people (95% 
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confidence interval: 3.1-4.8 million) who had ever been infected with HCV.2 Further 
RNA testing of anti-HCV-positive participants showed that 73.9% were chronically 
infected with HCV, corresponding to about 2. 7 million people. These prevalence 
estimates were recently updated with NHANES data collected from 1999 through 2002. 
Current prevalence estimates are 1.6% anti-HCV-positive, or 4.1 million people, and 
1.3% with chronic HCV infection, or 3.2 million people using current national population 
estimates. 1 Therefore, although incidence of acute HCV has declined significantly since 
the late 1980s, prevalence of chronic HCV has declined only slightly, and the total U.S. 
population chronically infected has increased. In the most recent NHANES study, 
relatively high prevalences of antibodies to HCV were seen in people between the ages of 
40-49 (4.3%); men (2.1 %); non-Hispanic blacks (3.0%), people living below the poverty 
threshold (3.2%), and current or former injection drug users between the ages of20 and 
59 (57.5%). Non-Hispanic black males aged 40-49 had 13.6% anti-HCV prevalence, 
which was significantly higher than most other demographic groups. 
It is important to note that NHANES participants are a representative sample of 
non-institutionalized civilians living within identifiable United States households. 
Therefore, active military, homeless people, prisoners, and others living in institutions are 
not included in the HCV prevalence estimates reported here. Because these are among 
the populations believed to be at high risk for HCV, NHANES probably underestimates 
overall HCV prevalence. Hepatitis testing in prisons is now common, and available data 
on hepatitis testing in state prisons indicates that approximately 27% of inmates may be 
HCV-positive; this statistic is based on facilities that conducted random or universal 
testing, rather than testing only of higher-risk prisoners. 19 The Department of Veterans 
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Affairs estimates that 5-10% of veterans using its health care system are infected with 
HCV, and offers an HCV testing and education program.Z0•21 
3.2: Risk Factors for HCV in the United States. There is consensus among 
HCV researchers and experts that the primary risk factor for having acquired HCV 
infection in the United States is a history of either past or present injection drug use or 
other percutaneous blood exposures, such as receiving blood transfusions before 1992, 
when highly sensitive screening of donor blood began22 In the most recent NHANES 
analysis described above, injection drug use was the factor most strongly associated with 
HCV infection. 1 With improvements in the safety of the blood supply, transfusions and 
other medical procedures are no longer a risk factor for new HCV infections in the 
United States. Other risk factors include a large number oflifetime sex partners, a 
history of sexually transmitted diseases, and being born to an infected mother. 22 
Nosocomial (health care-related) transmission is also possible. Although sexual history 
is considered a risk factor, long-term spouses of patients with chronic HCV infection are 
not usually considered to be at significantly elevated risk, although they may choose to be 
tested for peace of mind. These risk factors are evident in the guidelines CDC currently 
provides for determining whom should be tested for HCV infection, which appear in 
Figure I. 
CDC has also recommended that all HIV-positive people be tested for HCV23 
because of the similar risk factors for the two diseases and the likelihood that people will 
experience faster progression ofliver disease if they are co-infected with HIV and HCV. 
People with laboratory results suggesting possible liver disease, such as abnormal serum 
levels of alanine aminotransferase (ALT), should also be tested. 
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3.3: Natural History ofHCV. HCVis an enveloped virus in thejlaviviridae 
family. HCV exists in at least 6 genotypes; genotype 1 is responsible for most HCV 
infections in the United States, and genotypes 2 and 3 account for most of the rest.2 After 
initial (acute) infection, most people are asymptomatic, but some will experience vague 
flu-like symptoms that usually subside after several weeks. Following initial infection, 
some people will spontaneously clear the virus, but 60 to 85 percent of people with acute 
HCV will develop chronic HCV, which is diagnosed by the detection ofHCV RNA in 
serum for at least 6 months.24 Many patients with chronic HCV remain asymptomatic, 
but in some patients, the disease slowly and silently progresses to liver fibrosis which 
may lead to cirrhosis, end-stage liver disease (ESLD), and/or liver cancer (hepatocellular 
carcinoma, or HCC). The proportion of chronically infected people who develop 
cirrhosis within 20 years after initial infection is estimated at 1 0-15 percent overall, with 
substantial variability related to age at time of infection, gender, immunosuppression 
from HIV, and other concurrent infections such as HBV. Alcohol use is clearly 
associated with more rapid progression of liver disease from HCV?4 Advanced, severe 
cirrhosis can only be treated by liver transplantation. HCC can also follow fibrosis or 
cirrhosis, and HCC treatment may also involve liver transplantation. HCV is considered 
the primary reason for liver transplantation in the United States?4 
3.4: HCV Testing Procedures. As discussed earlier and shown in Figure 1, the 
CDC recommends testing for HCV infection for people considered to be at increased 
risk. Testing procedures for HCV are complex and not widely understood, even by many 
health care professionals25 ; several different testing methods are used alone or in 
combination. HCV testing usually involves an initial antibody screening test ("anti-
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HCV"), possibly using signal-to-cutoff (s/co) ratios, and/or followed by recombinant 
immunoblot assay (RIBA) to rule out false positives. Antibody tests cannot distinguish 
between acute, chronic, or resolved (cleared) infection. Therefore, for those testing anti-
HCV-positive, nucleic acid (RNA) testing is usually recommended to determine whether 
the individual is chronically infected. RNA tests may be either qualitative or 
quantitative; qualitative tests are more sensitive, but quantitative tests are useful to 
predict and monitor response to treatment26 Genotype identification is also important in 
predicting response to treatment and in making treatment decisions, since genotypes 2 
and 3 are associated with higher treatment success rates. Additional tests, including liver 
biopsy, are used to evaluate patients for treatment and to monitor disease progression. 
Liver biopsy, although not necessarily mandated, is considered the "gold standard" in 
determining course of treatment.26 
The CDC recently recommended a revised laboratory algorithm for HCV 
antibody testing and reporting, incorporating signal-to-cutoff ratios.Z5 Using a single 
antibody test without follow-up of positive results is not recommended; as with other 
screening tests, false positives can occur in populations with low prevalence ofHCV 
infection,25•26 and false negatives can occur also. 
Routine HCV screening of the general adult population is not currently 
recommended by CDC or other experts. Routine testing of pregnant women, and of the 
general adult population at no increased risk, has not been found to be cost-effective 
using mathematical models.27•28 CDC and the American Gastroenterological Association 
have recommended screening all HIV patients for HCV,23•29 but this recommendation 
does not appear prominently in the fact sheets and guidelines provided by CDC. 
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Published analyses of the cost-effectiveness and other issues surrounding HCV testing of 
HIV patients, and patients with other co-infections, are scarce. 
Policies and issues related to HCV screening and testing in North Carolina and 
other states are discussed further in Section 7 of this paper. 
3.5: HCV Treatment. HCV treatment issues are even more complex than HCV 
testing issues. The goal of treatment is to achieve a sustained virological response 
(SVR), which is usually defined as a six-month absence of detectable virus following a 
defined course of treatment. Although relapses do occur, the long-term prognosis for 
patients who clear the virus is excellent; successfully treated patients can usually expect 
no further progression of liver disease, and some experts consider an SVR to be 
equivalent to a cure. The current "gold standard" of treatment is pegylated interferon 
alfa, injected once a week, plus oral ribavirin daily, for up to 48 weeks; the duration of 
treatment varies depending on the patient's HCV genotype and response to treatment 
during the first 12 weeks.26•29•30 The overall proportion of patients who achieve an SVR 
has been estimated at 54% to 56%. Patients with genotypes 2 and 3 respond more 
quickly and are more likely to achieve an SVR than patients with genotype 1.Z6•30 
Research is ongoing to determine the optimal treatment strategies for individual patients, 
based on early virological response, viral load, and other factors. 30 
Although more than 50% of patients succeed in initial treatment for chronic HCV, 
research continues on how best to treat the nearly 50% of initial "non-responders", as 
well as those who relapse later or who discontinue treatment because of severe or 
debilitating side effects. Side effects of interferon and ribavirin can be significant, 
including flu-like symptoms, marrow suppression, emotional and sleep disorders, 
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autoimmune disorders, and many other medical problems.29 Patient groups not 
recommended for treatment include pregnant women, people with uncontrolled mental 
illness, and people with other severe co-morbid conditions. Patients who already have 
decompensated (advanced) cirrhosis are not treatable, but instead are referred for liver 
transplantation. Patients who are current injection drug users or alcohol abusers are 
recommended for HCV treatment only in conjunction with treatment for these 
behaviors.29 Because of the complexities involved in treating HIV and HCV co-infected 
people, data are scarce to support HCV treatment decisions for HIV -positive individuals, 
but existing models suggest that HCV treatment can be successful and cost-effective in 
this population; additional research is needed.31 •32 
The cost ofHCV treatment is typically quite high, depending upon the length of 
therapy and the combination of medications used. Salomon et ai33 estimated the cost of a 
standard 48-week course of combination therapy for genotype 1 at $18,507 in 2001 US 
dollars, not including the associated costs for medical evaluation and monitoring. 
Published average wholesale prices for one of the pegylated interferon products, Roche's 
Pegasys ™, were more than $1500 per month in 2005.34 These prices do not include the 
costs associated with testing, monitoring, and medications possibly prescribed to combat 
side effects, such as anti-depressants. 
The expense, long course of therapy, side effects, and relatively low efficacy of 
current treatments have significant implications for the burden of chronic HCV disease. 
When a patient tests positive for HCV and is found to be experiencing chronic HCV 
progression, the decision of whether and when to initiate treatment is complex. 
Unfortunately, it is difficult to obtain state-level (or even national-level) data on the 
20 
number of patients undergoing treatment, the proportion of patients achieving SVR, and 
similar measures. In summary, more efficacious and less expensive therapies are 
desperately needed to treat chronic HCV patients. Fortunately, several newer therapies 
are in clinical trials, and some of these should become available within the next five 
years. 35,36 
4. EPIDEMIOLOGY OF HEPATITIS C IN NORTH CAROLINA 
4.1: Prevalence and Mortality. Reliable prevalence estimates for chronic HCV 
are generally unavailable at the state level. Although some states have surveillance 
systems for chronic HCV, most states estimate the number of residents with chronic HCV 
by extrapolating the national prevalence estimates from NHANES to the state population. 
The complexity of testing need to diagnose either acute or chronic HCV, and the need to 
use additional RNA testing to confirm chronic disease, hinder any state's ability to use 
surveillance systems to monitor prevalence of chronic disease. 
Chronic HCV is not a reportable disease in North Carolina, although acute HCV 
is reportable; North Carolina uses the most current (2004) CDC acute HCV case 
definition of acute HCV to screen suspected cases. This definition is restrictive, 
requiring clinical symptoms of acute illness along with verifiable laboratory criteria such 
as elevated liver function tests (high ALT and/or AST levels), confirmed antibody to 
HCV, and negative antibody tests for HAV and HBV.37 Using this case definition, there 
were 13 cases of acute HCVreported in North Carolina in 2003; 12 cases in 2004; and 21 
cases in 2005.38 Given that acute HCV is often asymptomatic and patients are usually 
unaware of their initial infection, it can be assumed that acute cases are significantly 
under-reported. Therefore, reporting of acute HCV cases yields little useful information 
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about the prevalence ofHCV antibodies in North Carolina residents, nor about the 
prevalence or burden of chronic HCV in the state. 
Mortality data is obtained from death certificates, using the ICD-1 0 disease codes 
for classification of the underlying cause of death. North Carolina imd United States 
deaths and age-adjusted death rates for 1999 through 2003, for acute and chronic HCV 
combined, appear in Table I. The age-adjusted death rates for both the state and the 
country increased between 1999 and 2001, and then were fairly stable for 2001 through 
2003. The proportion of the United States deaths that occurred in North Carolina grew 
from 2.1% to 2.6% during this period of time. In 2003, the death rate per I 00,000 
persons from HCV in North Carolina was 1.4, compared with 1.6 for the United States as 
a whole. 
Because these statistics do not include all deaths possibly caused by HCV from 
conditions such as advanced liver disease or liver cancer, they are clearly underestimates 
of the mortality associated with HCV. However, deaths from those related conditions 
could be attributed to other causes, such as HBV. Therefore, without making additional 
assumptions (such as the proportion of deaths from liver cancer, cirrhosis, etc., that are 
attributable to HCV), the state and national mortality statistics are oflimited use in 
determining the absolute impact ofHCV in North Carolina. Additional comparisons of 
the North Carolina and U.S. populations with respect to HCV risk factors are given in the 
next section. 
4.2: Size of Populations at Risk in North Carolina. Current (2004 and 2005) 
population estimates for North Carolina and the United States are shown in Table 2. 
Estimates are also given of the number of middle-aged black males (by age group), 
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prisoners, and HN-infected individuals living in North Carolina, compared with the 
United States as a whole, because these groups have been identified as high-risk for 
chronic HCV disease. As shown in Table 2, North Carolina is now home to about 2.9% 
of the US population. 39 The gender and age distributions in North Carolina are very 
similar to those in the U.S. as a whole. Table 2 also shows that North Carolina has a 
proportionally greater population of minorities, especially African-Americans, and more 
African-American men compared with the U.S. as a whole. North Carolina also has 
more people living with HIV/AIDS than does the United States overall, but North 
Carolina has fewer prisoners per 100,000 persons than in the U.S. overall. 
As discussed earlier and shown in NHANES and other research, current or former 
injection drug users are probably the group at highest risk for acute or chronic HCV 
infection. Unfortunately, data are scarce to determine the number of current or former 
injection drug users in North Carolina. Some national surveys of drug abuse, such as the 
National Survey on Drug Use and Health, provide estimates of the current national 
prevalence of injection drug use and other illegal drug use, but data on former injection 
drug use is difficult to find at the state level. 
4.3: Liver Transplants in North Carolina. Liver transplant data is publicly 
available. Table 3 provides the number ofliver transplants performed in North Carolina 
and in the United States from 1996 through 2005. About 2.4% of all the liver transplants 
performed from 1988-2006 (to date) were performed in North Carolina. The number of 
liver transplants in North Carolina was actually higher in 2000 than in the past five years, 
but the number of liver transplants nationwide has been steadily growing for the past ten 
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years. The OPTN states that chronic HCV-associated cirrhosis has been increasing, and 
accounted for 43% ofliver transplants in 2004.40 
In summary, available epidemiological data, population demographics, and liver 
transplant data provide only a few clues to the extent of the impact of chronic HCV in 
North Carolina. Mortality data, population demographics, and liver transplant data 
suggest that the prevalence and costs ofHCV in North Carolina may be approximately 
proportional to the national HCV burden, or possibly somewhat lower on a population 
basis, i.e. between 2.0% and 2.9% of the national burden. The next section of this paper 
summarizes the findings from earlier, published cost estimates and forecasts of the 
national impact of chronic HCV. 
5. PUBLISHED ESTIMATES AND FORECASTS OF THE COST OF HEPATITIS 
C IN THE UNITED STATES 
5.1: Existing National Cost of Illness Estimates and Models. In 1998, the 
Centers for Disease Control and Prevention conservatively estimated the cost ofHCV in 
the U.S. at $600 million per year.22 Subsequent authors pointed out that no clear basis for 
this estimate was ever provided, and that it was probably far too low6 •41 In recent years, 
several published data analyses and models have addressed the costs and burden ofHCV 
at a national level. For example, Wong et al4 developed a mathematical model using 
Markov cohort simulation to project morbidity, mortality and costs from HCV in the U.S. 
through 2019. The model predicted annual medical care costs of approximately $1 
billion (in 1999 dollars) in the year 2006.4 This estimate included only variable, direct 
treatment costs associated with caring for a HCV patient in a university hospital, and did 
not include "indirect" economic costs such as lost wages or suffering. 
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Leigh et al41 developed a detailed, comprehensive estimate of the economic costs 
ofHCV, using a "top-down" methodology and including both direct and indirect costs. 
They concluded that in 1997 dollars, HCV cost U.S. society $5.46 billion, of which about 
one-third ($1.8 billion) were direct costs. Of the direct costs, $1.4 billion were estimated 
to be medical (not administrative) costs. Leigh eta!. provided comparisons of their 
assumptions with those of Wong, and defended the accuracy of their comparatively much 
higher estimates. 
Kim et a16 used the Nationwide Inpatient Sample (NIS) of the Healthcare Cost 
and Utilization Project (HCUP) data, for the year 1995 only, to investigate 
hospitalizations, charges, and mortality for liver diseases caused by HCV and, in 
comparison, alcohol-induced liver disease. They concluded that in 1995, there were 
64,800 hospitalizations related to HCV, of which 26,700 were "liver-related" 
hospitalizations. Of the 26,700 "HCV and liver-related" hospitalizations, there were 
2600 in-hospital deaths. The total hospital charges associated with these hospitalizations 
were $514 million (in 1995 dollars), and the total in-hospital visit days were 207,600. 
These results imply an average length of stay of7.8 days per visit, and average charges of 
$19,251 per visit. Charges per hospitalization varied by a factor of more than 10, 
depending on whether liver transplantation occurred. Kim et a! also investigated factors 
associated with in-hospital death and hospitalization charges. 
In a separate article, Kim 7 also investigated mortality, liver transplants, and 
hospitalization statistics related to HCV, through 1999,2000, and 1998, respectively. 
Again using data from HCUP, Kim estimated the total hospital charges for HCV in 1998 
at $1.03 billion (1998 dollars), which was nearly double the estimate from 1995 ($528 
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million in 1998 dollars). Kim also concluded that in 1998, approximately 2% of all 
hospital discharges listed an HCV diagnosis. 
Building on the work of Kim eta!, Grant et a15 investigated growth trends in the 
inpatient, outpatient, and prescription drug costs associated with HCV. They analyzed 
the national inpatient database from HCUP through 2001, as well as data from the 
National Ambulatory Medical Care Survey and the Verispan Source Prescription Audit. 
Grant et a! found consistent, strong growth trends (22%-31% average annual growth 
rates), in each ofHCV-related hospitalizations, HCV and liver-related hospitalizations, 
HCV hospital days, charges, and deaths, for 1994-2001. They also found that outpatient 
office visits by HCV patients increased at an average annual rate of36%, and that 
spending for HCV drug treatment increased each year over the time period studied. In 
the supplemental tables for their paper, they reported 277,430 hospitalizations with a 
diagnosis ofHCV; 92,694 HCV-and liver-related hospitalizations; and about $2.5 billion 
in HCV -and-liver-related hospitalization charges in the year 2001. 
5.2: Implications for North Carolina. The published analyses summarized in 
the previous section are consistent in concluding that the morbidity, mortality, and 
economic impact of HCV in the United States is substantial and is growing. However, 
these analyses were conducted at different times and using different methods. The most 
recent analysis, by Grant eta!, used data only through 2001. These analyses need to be 
updated in order to determine whether the growth trends in HCV hospitalizations, deaths, 
and costs have continued beyond 2001. 
The previous analyses were conducted at a national level only; they include no 
results specific to any individual state. Federal funding is scarce for state and local HCV 
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programs. Therefore, from the point of view of state and local policy, there is a need to 
determine the size of the economic impact ofHCV in North Carolina, and assess whether 
state-level indicators such as hospital charges are growing at the very high (20-30% per 
year) annual rates seen in the national studies conducted previously. Accordingly, the 
next section of this paper presents an original analysis of the North Carolina Hospital 
Inpatient Data. Also reported are statistics on the costs ofHCV to the state Medicaid 
system; these were provided by the North Carolina State Center for Health Statistics. 
6. ANALYSIS OF NORTH CAROLINA HOSPITAL INPATIENT DATA AND 
MEDICAID STATISTICS 
6.1: Data Sources. The major data source used for this analysis was the North 
Carolina Hospital Inpatient Discharge Database for the fiscal years 1996-2004.42 This 
time period was chosen because the database does not include the year 1995 (although it 
does include earlier years); the discontinuity hinders the potential analysis of even longer 
trends. In addition, a nine-year time period was more than sufficient to answer the key 
research questions. The database contains discharge records abstracted from claim forms 
for most hospitals in the state, including acute care licensed hospitals, rehabilitation 
facilities, and psychiatric and substance abuse facilities, with the exception of four state 
psychiatric hospitals.43 This database is not a sample; it represents the majority of 
hospital discharges in North Carolina. A subset of this database was obtained, containing 
all discharge records in which an HCV diagnosis, either chronic or acute, appeared in any 
diagnosis field. Access to the entire database of hospital discharges was not possible. 
Summary statistics describing the entire database were also obtained from the Sheps 
Center for purposes of comparing overall trends with HCV -related trends. 
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Medicaid claims statistics for North Carolina for the calendar years 2003-2005 
were requested from and generated by a staff member at the State Center for Health 
Statistics (J. Timothy Whitmire, SCHS). Data for years before 2003 were not available. 
For the analysis, the SCHS used a subset of Medicaid claims data in which every claim 
record had some diagnosis ofHCV. They were unable to include every claim that might 
have been associated with an HCV diagnosis because some claim types, such as 
pharmacy claims, do not include a diagnosis code. Therefore, their results may represent 
underestimates of the total number of Medicaid patients with HCV and the total costs 
associated with HCV diagnoses. 
6.2: Research Questions. The primary goal of the hospital inpatient data 
analysis was to quantify North Carolina hospital stays (discharges), days of stay, and 
inpatient hospital charges, in terms of both annual values and growth trends, by patient 
groups including age, gender, and payer status. Basic counts, sums, means, and trend 
statistics, including compound annual growth rates and simple average annual growth 
rates, were computed as described in the Methods section below and defined in the 
Glossary. Additional research questions addressed in the inpatient hospital data analysis 
were the extent of the inpatient mortality associated with HCV and liver-related 
diagnoses, and the proportion ofHCV and liver-related hospital discharges in which the 
patient also had a diagnosis ofHIV/AIDS. 
The goals of the Medicaid claims data analysis were to evaluate the magnitude 
and trends of the costs of HCV to the NC Medicaid system, the number of Medicaid 
clients with any diagnosis ofHCV, by age, race, and gender, and the distribution of 
Medicaid costs by claim type (e.g., outpatient vs. inpatient claims), for 2003-2005, which 
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were the years available. The costs to the Medicaid system were determined from actual 
paid claims records; therefore, they represent variable, direct medical costs to society and 
to the state government. 
6.3: Methods. The same ICD-9-CM diagnosis codes were used to select records 
from both the hospital inpatient and Medicaid databases. The HCV diagnosis codes and 
their definitions are shown in table A-1 of the Appendix. Counts of visits with "acute or 
unspecified" HCV diagnoses were compared with the number of visits with chronic 
diagnoses in the inpatient database, and with the number of acute HCV disease reports in 
North Carolina. Based on these comparisons, it appeared likely that the majority of 
diagnoses of"acute or unspecified" HCV were actually chronic cases. For this reason, 
and to be consistent with the methods used in previous studies by Kim and Grant, 
acute/unspecified HCV as well as chronic HCV diagnoses were included in both the 
hospital inpatient data analysis and the Medicaid data analysis. 
Two levels of analysis were conducted using the hospital inpatient database. In 
the first level, the full database was used, consisting of all discharges (hospital stays) 
from participating North Carolina hospitals in which any diagnosis ofHCV was 
recorded, 1996-2004. In the second level analysis, termed the "HCV and liver related" 
analysis, the database records with HCV diagnoses were partitioned further to create a 
subset in which the hospital stays and associated charges for this subset are highly likely 
to be directly attributable to HCV. The criteria used to create this more selective 
database were developed based on the prior work by Grant and Kim, and were verified 
with Dr. Grant (William Grant, Ph.D, oral and written communication, September 2006). 
A hospital stay was included in this subset ifHCV was coded in the primary diagnosis 
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field, indicating that HCV was the main reason for hospital admission; or if, in addition 
to a non-primary diagnosis ofHCV, there was also any diagnosis of a form ofliver 
disease attributable to HCV, such as cirrhosis or other chronic liver disease; liver cancer; 
ascites (abdominal fluid); or a liver transplantation procedure. 
For each level of the analysis, descriptive statistics were computed for North 
Carolina hospital stays (discharges), days of stay, inpatient hospital charges per stay, and 
days per stay. Because a small proportion of hospital stays involve liver transplants or 
other extremely expensive procedures, the distribution of charges per stay is quite 
asymmetric. For this reason, both mean and median charges per stay were calculated, and 
the standard errors for the mean charges per stay are reported for each year. For the 
"HCV and liver related" analysis, the number and proportion of hospital stays resulting in 
death and stays for patients co-infected with HIV/AIDS were also determined by age 
group. 
To investigate whether the long-term trend patterns are similar to recent trends, 
the compound annual growth rate (CAGR) was computed both for the entire nine-year 
period and also for only the latest four years, 2001 through 2004. The CAGR is a 
frequently used measure of annual growth that is simple to calculate because it relies only 
on the first and last year's observations. However, if the observed time series data do not 
show consistent growth over time or if the last year's observation is atypical, the CAGR 
may not be a reliable indicator of growth. Therefore, the average annual year-on-year 
growth rates for the entire nine-year period are reported as well. The CAGR and the 
average annual growth rates are often quite similar; both measures are included for 
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completeness and to facilitate comparison with previous research. Formulas and further 
definitions for both measures are provided in the Glossary. 
Sampling weights are not included with this database; all observations (hospital 
stays/discharges) were weighted equally. All hospital charges were adjusted to 2005 
dollars using the Medical Consumer Price Index. The data were checked for errors and 
missing observations. Analysis was also conducted by age group, gender, and payer. For 
the hospital data analysis, race was not used as a subgroup classification because a 
significant percentage of observations contained missing or unknown values for race. 
For the North Carolina Medicaid claims database, total claim amounts and counts 
of Medicaid recipients by age group, gender, and race were reported. Because only three 
years of data were available, the year-on-year growth rates in each of the two intervening 
years (2003-2004 and 2004-2005) were computed and reported, instead of the CAGR or 
average annual growth rate. 
6.4: Results from North Carolina Hospital Inpatient Data. Results from the 
analysis of the hospital inpatient database are given in Tables 4 through 11 and Figures 2 
through 4, and are summarized in this section. Additional details on the number of 
hospital discharges by year, for both levels of database analysis, are provided in Tables 
A-2 and A-3 of the Appendix. 
Counts and totals for the number of hospital discharges, hospital days, and total 
charges were obtained for the entire North Carolina Hospital Inpatient Database, 
regardless of diagnosis. Growth rate measures (CAGR for the whole time period, 
average annual growth rates, and CAGR for 2001-04 only) were calculated for 
comparison with the two HCV subsets used in this analysis. The results are provided in 
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Table 4. Total North Carolina hospital discharges and days grew at annual rates of only 
about 1% to 2%, over both the longer (1996-2004) and more recent (2001-2004) time 
periods. North Carolina hospital charges, adjusted for inflation, grew at about 5% per 
year for the longer time period, and grew more rapidly (8.9% per year) during the most 
recent years. Total North Carolina hospital discharges and charges were also compared 
with discharges and charges for stays with any diagnosis ofHCV; the results are shown 
in Figure 2. The proportion of hospital discharges with any diagnosis ofHCV grew 
steadily from about 0.2% in 1996 to 1% in 2004, while the proportion of hospital charges 
with any HCV diagnosis grew steadily from about 0.3% to 1.2%. Although increased 
awareness ofHCV may be partly responsible for the increasing relative levels ofHCV-
related hospital utilization, these trends are still quite striking. 
The total number of hospital discharges with any HCV diagnosis, by age group, 
gender, and payer group, is shown in Table 5; Figure 3 graphically depicts the age group 
trends. Table 5 also provides the three growth rate measures for the trends in discharges 
over time. It can be seen from Table 5 that the total number ofNorth Carolina hospital 
stays associated with HCV diagnoses grew at about 25% per year for the nine-year 
period, but in the past four years, the CAGR was about 17% per year. As expected from 
previous studies, males are hospitalized with HCV diagnoses more often than females. 
People aged 45-54 experience the most HCV-associated hospital stays, followed by 
people aged 35-44 (see Figure 3). However, Table 5 also shows that in more recent 
years, the growth rates have shifted so that the CAGR is now highest in the 55-64 age 
group; discharges for the 25-34 and 35-44 age groups are growing at slower rates than in 
the past. About 28% of hospital stays were charged to Medicaid, and more than 60% 
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were charged to either Medicaid or Medicare. The annual rates of growth in hospital 
discharges are currently higher in the Medicaid population than in other payer groups, 
with a CAGR of more than 20% from 2001-2004. 
Although the rate of annual growth in HCV-re1ated discharges appears to be 
somewhat lower than in the past, it is still quite high. Nearly all subgroups were still 
experiencing more than 10% annual growth during the past four years; only the 25-34 
and 35-44 age groups showed recent growth rates less than 10% per year. Among the 
age groups, the highest growth rates occurred in the 45-54 and 55-64 age groups (see 
Table 5); this result is consistent with the predictions of previous research. 
It can be seen from Table 6 that hospital charges are increasing at about the same 
rates as discharges; the annual growth rates in total charges were approximately 26% per 
year for the entire time period, with only slight decline to 24% CAGR in 2001-2004. In 
2004, more than $200 million (in year 2005 dollars) was charged by North Carolina 
hospitals for inpatient stays with any diagnosis ofHCV. The increases in charges over 
time can be attributed mainly to growth in the number of stays and in charges per stay, 
not in longer hospital stays; the average length of stay actually appears to be decreasing 
steadily over time, and is now about 6 days per stay. Both the mean and median charges 
are reported because, as noted in previous research, they are quite different. The high 
costs of liver transplants and other expensive procedures cause the distribution of charges 
to be skewed; the mean charges are nearly twice the median charges. The mean and 
median charges per stay decreased in 1999-2000, but in recent years (2001-2004), they 
have been increasing at 6 to 7 percent per year. Tables 5 and 6 clearly show that the 
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growth rates in hospital utilization related to HCV are much higher than the growth rates 
for overall North Carolina hospital utilization, reported in Table 4. 
Table 7 summarizes hospital discharges for the more selective, "HCV and liver 
related" database subset. Hospital stays included in this analysis are most likely directly 
attributable to HCV. Hospital discharges attributable to HCV are growing at double-digit 
(more than 10%) annual rates overall and in most subgroups. The overall rate of growth 
as measured by the CAGR has slowed somewhat in the past few years, to 12.9% per year. 
However, in some age groups (45-54 and 55-64), the CAGR is sti1118 to 20 percent. The 
burden ofHCV hospital visits is heavily concentrated in the 45-54 age group (44% of 
stays over the entire time period), and it appears to be shifting from younger to older age 
groups. As the population infected with HCV continues to age, the number of visits in 
the 25-34 and 35-44 age groups is beginning to decline, as shown in Figure 4. Table 7 
also shows that the number of hospital stays is still growing by more than 15% per year 
for both Medicaid and Medicare recipients. The proportion of stays by gender has not 
changed over time; men comprise about two-thirds ofHCV and liver-related hospital 
stays. 
It can be seen from Table 8 that the hospital charges in 2004 for the HCV and 
liver-related hospital stays were over $70 million in 2005 dollars. The CAGR for these 
charges was more than 20% for the entire time period, and more than 18% for the more 
recent period, 2001-2004. These growth rates appear to be mainly attributable to the 
growth in hospital stays, as well as recent growth in the mean charge per stay. Table 9 
provides detailed hospital charges for patients with both HCV and liver-related diagnoses 
by age group and payer. The age group differences are particularly striking in Table 9. 
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Charges for the 35-44 age group have shown slower growth in recent years (6.1% CAGR 
for 2001-2004), but charges for the 55-64 age group are consistently growing at annual 
rates exceeding 30%. It can be predicted from Tables 8 and 9 that if hospital charges 
attributable to HCV continue to grow at these rates (and assuming continued medical 
price inflation of about 4% per year), the total North Carolina hospital charges for HCV 
and liver-related stays will be at least $102 million in 2006 ($70.6 x 1.18 x 1.18 x 1.04). 
This represents a 140% increase compared with the charges incurred in 2001. Based on 
the age group differences and the growth rates for the 55-64 age group, it seems likely 
that the Medicaid and Medicare programs will continue to bear a significant burden for 
HCV and liver-related hospital charges. Tables 7 through 9 can be compared with Table 
4; it is clear that North Carolina HCV and liver-related hospital utilization has grown far 
more rapidly than North Carolina hospital utilization overall. 
Estimates of mortality from HCV following North Carolina hospital stays are 
given in Table 10. The number of patients who died following an HCV and liver-related 
hospital stay in North Carolina grew from 65 in 1996, to 252 in 2004, representing a 
CAGR of more than 18%. These deaths were heavily concentrated in the 45-54 age 
group. Deaths as a proportion of all HCV and liver-related hospital outcomes declined 
very slightly over time, from 8.8% to 7.8%. The number of deaths identified through this 
analysis of hospital records can be compared with the state mortality data shown in Table 
1. Clearly, there are more deaths attributable to HCV (as shown in Table 1 0) than the 
official mortality data would suggest; for example, in 2003, 119 HCV deaths were 
officially reported in North Carolina, but 198 deaths were associated with HCV and liver-
related hospital stays for 2003. This result is not surprising, since the selection methods 
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used in this analysis should identify more HCV-attributable deaths than the reporting 
system used for death certificates can identify. 
As will be discussed further in Sections 7 and 8 of this paper, current research and 
resources are focusing on the population co-infected with HCV and HIV. For this reason, 
and for comparison with previous research, the number of hospital stays for patients 
diagnosed with both HIV/AIDS and HCV and liver-related disease was analyzed. The 
results appear in Table 11. The number of hospital stays for co-infected patients 
increased substantially from 1996 to 2004, but these stays remain a relatively small 
proportion (about 5%) of overall stays. This proportion declined from 1996 through 
2004, but is still slightly larger than the national proportion estimate reported by Grant et 
a!., which was 2 to 3 percent. 5 Slightly different criteria for identifying HIV/ AIDS 
diagnoses may explain the difference in results. 
6.5: Results from North Carolina Medicaid Claims Data. The results from 
the North Carolina Medicaid claims database are shown in Tables 12 and 13. In 2005, 
nearly $32 million was paid from the state Medicaid program for claims with any 
diagnosis ofHCV. Trends are difficult to assess because only three years of results were 
available; therefore, growth rates are given for each one-year growth period. However, it 
appears that the total paid claim amounts related to HCV grew at rates well above 
inflation in 2004 and 2005. The majority of the paid claim amounts were for inpatient 
hospital visits. Table 13 shows that the number of Medicaid recipients with any 
diagnosis ofHCV grew over this time period as well, from about 6800 recipients in 2003 
to about 8200 in 2005. The majority of these recipients (53-54%) were white, and most 
oftbe remainder (36-37%) were black. HCV-diagnosed Medicaid recipients were 
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concentrated in the 35-44 and 45-54 age groups, but the proportion in the 35-44 group 
declined, while the proportions in the 45-54 and 55-64 age groups grew steadily each 
year; this is consistent with the age group trend patterns seen in the hospital data. 
Rather surprisingly, the majority of North Carolina Medicaid recipients with HCV 
were women; this probably reflects the characteristics of the overall Medicaid population. 
Recipients diagnosed with HCV represent a fairly small minority of the total North 
Carolina Medicaid population, which is not surprising since the majority of Medicaid 
recipients are children, who rarely have HCV disease. 
6.6: Limitations and Strengths of Analysis. A limitation to the hospital 
discharge data analysis is that charges, not actual economic costs, were analyzed. 
Because hospital inpatient charges may overstate the actual economic costs to society, 
some researchers advocate using cost-to-charge ratio adjustments, which was not done 
here (nor was it done in the previous studies by Grant et al and Kim et al.) Cost-to-
charge ratios are multipliers that are sometimes applied for each hospital (or by state or 
region) to approximately convert charges to true, direct hospital costs. However, it is 
well known that using cost-to-charge ratios still does not guarantee accurate measurement 
of direct costs. Furthermore, cost-to-charge ratios would only change absolute estimates 
of hospital charges, and would not significantly affect the measurement of trends. 
Therefore, although the charges reported here may be overestimates of the direct hospital 
costs, the trends are probably fairly accurate. 
Another limitation to this analysis is that inpatient hospital charges were the only 
direct medical costs addressed. Other categories of direct medical costs include 
outpatient hospital costs, physician office visit costs, and medication costs. Also, 
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indirect economic costs, such as patients' lost productivity/wages and caregiver costs, 
were not examined. Other researchers have addressed these categories of costs for HCV, 
especially in the context of comprehensive cost-effectiveness analyses. However, this 
analysis is intended to be a descriptive analysis of state-level trends, rather than a 
comprehensive cost-effectiveness study. Considering the high expense and low efficacy 
ofHCV medications, as discussed earlier in this paper, it would be useful to quantify the 
costs and outcomes ofHCV treatment in North Carolina; this is an area for further 
research. 
A major limitation of this study is that the unit of observation of the inpatient 
hospital database is hospital stays, not patients. The number of hospital discharges over 
time is not equivalent to the number of patients, because multiple visits per patient are 
possible, either within the same year or across multiple years. Because HCV-related 
conditions can be quite serious and may require long-term treatment, multiple visits per 
patient are probably quite likely. The data use agreement limits the analysis of the data 
so that individual patients cannot be identified. Longitudinal analysis, i.e. investigation 
of patient outcomes over time, was therefore impossible in this study. A patient registry 
or other primary data source, using individual patient identifiers, would need to be 
obtained in order to make longitudinal analysis possible. 
This analysis also has several strengths. The methods used to identify HCV and 
liver related hospital stays have been used in previous research, so the results given here 
can be compared with earlier work. This analysis included data from a long time period; 
striking trends, consistent with earlier research, were observed and quantified. The North 
Carolina hospital inpatient database is not a sample, but a near-census of hospital stays 
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and charges based on hospital claims, so bias in the data and results is probably minimal. 
The large number of observations (hospital discharge records) in the database facilitated 
the reporting of results by age group, gender, and payer status. 
In addition, this analysis (in contrast to several previous studies) is not a 
predictive model based on assumptions about uncertain parameters such as HCV 
incidence, prevalence, disease progression rates, and disease-state costs; rather, it is a 
descriptive analysis of trends in actual hospital stays, charges, and Medicaid claims. As 
such, it provides some indication of recent and current trends in actual costs to society, 
using minimal assumptions. This analysis helps to answer the question "What is the 
impact right now?" rather than the question "What might the impact be in the future?" 
7. HCV TESTING POLICY IN NORTH CAROLINA AND OTHER STATES 
7.1: HCV Testing in Other States. As discussed earlier, HCV testing is 
recommended for people considered to be at increased risk of infection. However, there 
is a variety of guidelines and opinions about which specific populations are at increased 
risk and should be tested. The few national HCV screening programs that exist have 
focused on easily identifiable, high-risk populations including prisoners19 and veterans.21 
There are many other people at increased risk for HCV who are harder to identify, and 
who may not have convenient access to HCV screening, counseling, and treatment; these 
populations include the homeless, former prisoners, people who had blood transfusions 
before 1992, and current or former injection drug users, including people who 
experimented with drugs only briefly or even only once. 
The CDC provides funding for hepatitis C coordinators in each state, 44 but 
currently does not provide funds for testing or education programs. Because of the 
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shared risk factors for HCV and HIV, and in order to maximize benefits from limited 
funds, the CDC's National Hepatitis C Prevention Strategy relies upon integrating HCV 
services into existing public infrastructure for HIV, other STD's, and drug abuse.44 
Testing HIV-positive people and others who present at STD clinics for HIV testing may 
be relatively convenient and inexpensive, compared with reaching out to broader 
populations. However, according to CDC estimates, about 1.0 to 1.2 million Americans 
are living with HIV/AIDS,45 and about 30% of these are co-infected with HCV.46 This 
equates to about 300,000 to 360,000 co-infected Americans, which is only about 10% of 
the national population estimated to be chronically infected with HCV. The rates of co-
infection with HCV and other STD's are not well known. Therefore, targeting HIV-
positive people and other STD patients for HCV testing can probably identify only a 
small percentage of all people with chronic HCV infections. 
Emphasizing risk factors such as injection drug use or existing HIV infection 
when evaluating patients for HCV testing may lead to fears of stigmatization and may 
discourage people from being tested. The CDC and others have not recommended testing 
the general adult population for HCV, but an argument can be made that because of the 
stigma associated with admitting risk factors such as HIV or injection drug use, testing 
should be made available to anyone who suspects he or she may be infected without 
requiring that the patient provide a reason. Some testing program providers, such as the 
Veterans Administration, are sensitive to the issue of stigmatization and are more lenient 
in their guidelines about whom should be tested. The VA simply includes as a criterion 
for testing "If you wish to be tested" and adds "It's OK to get tested if you just want to 
know your status.',21 
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Due to the high cost of RNA testing and other follow-up testing, some HCV 
screening programs provide anti-HCV testing only, without confirming whether positive 
results are false or whether the infection is resolved or cluonic. Unfortunately, additional 
testing and follow-up is much more expensive than simple anti-HCV screening, and is 
therefore more challenging to include in free or reduced-cost testing programs. 
Some states, such as Florida and Wisconsin, have used specially designated HCV 
funds to make HCV testing and other HCV services available for free in many local 
health departments and other public health clinics.47•48 From a 2004 survey of state HCV 
Coordinators, the CDC estimated that 55% of states (22 of 40 states responding) offered 
any access to HCV testing in publicly funded clinics, such as STD clinics and HIV 
counseling and testing sites. In addition, 77.5% (31 of 40 states responding) had a 
registry for tracking cluonic HCV cases49 North Carolina had neither publicly funded 
HCV testing nor a chronic HCV registry at the time of that survey, and still has neither of 
these items. 
More recently, the National Alliance of State and Territorial AIDS Directors 
(NASTAD) initiated an assessment of the 52 hepatitis C coordination programs funded 
by CDC (one coordinator is currently funded for each state, the District of Columbia, and 
the Indian Health Service). This assessment includes a survey to obtain updated 
information on the availability and funding levels (if any) for HCV testing and education, 
registries, and other programs, by state. Data from this survey are being analyzed by the 
CDC and results should be available in late 2006 (Chris Taylor, NASTAD, written 
communication, October 2006). 
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7.2: HCV Testing Programs in North Carolina. Although free testing for HCV 
antibodies is not available through local health departments in North Carolina, there are a 
few free testing programs provided via federal and other grants. The Piedmont HIV 
Integrated Community Access System (PHI CAS), in collaboration with the Durham 
County Health Department and the Duke Medical Center, offers a free HCV testing 
program at the Durham County Health Department. Patients are seen in the Health 
Department's STD clinic, are assessed, and are offered testing if they have specific risk 
factors for HCV infection (Beth Stringfield, PHI CAS, oral communication, July 2006). 
Consistent with the mission of PHI CAS, there is an emphasis on identifYing and 
providing services for people co-infected with HCV and HIV.50 If continued funds are 
available, PHI CAS plans to implement HCV testing in Person County as well. 
Through the state HIV/STD Branch, one-time funds have been contracted to the 
Gaston County Health Department to provide free testing for all STD patients and others 
at risk who are eligible to be screened for HCV. At this time, these are the only two 
known public facilities or locations at which free HCV screening is available in North 
Carolina. The North Carolina Viral Hepatitis Task Force is working to identify resources 
and develop additional programs for HCV testing, education, awareness, and treatment. 
The final section of this paper presents conclusions, recommendations for further 
data collection and analysis, and recommendations for changes to state HCV policy. 
8. CONCLUSIONS AND RECOMMENDATIONS 
8.1: Summary and Conclusions. As shown in Section 6, North Carolina is 
clearly not immune to the burden of the "sleeping giant," as HCV has been called. The 
results presented in Section 6 indicate that North Carolina HCV hospital visits, Medicaid 
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utilization, and costs/charges all show substantial growth rates that cannot be attributed to 
overall growth in North Carolina hospital utilization. Although annual growth rates for 
these measures are slightly lower in later years than in the earlier years of the time period 
stndied, they are still growing in "double digits" (at least 10% CAGR) in nearly all 
groups, with very high growth rates (more than 30% CAGR) in some population groups. 
The growth in hospital charges can be attributed mostly to the growth in the number of 
stays, but is also partly due to recent growth in the average charge per stay. 
The trends in hospital utilization measures vary by age group. The burden of 
HCV hospital stays and charges is now heavily concentrated in the 45-54 age group. The 
45-54 and 55-64 age groups are experiencing the highest growth rates in hospital stays 
and charges directly attributable to HCV. As these "baby boomer" population segments 
continue to age, new HCV patients are identified, and existing patients continue to 
experience disease progression, the number of hospital stays and charges for these age 
groups is almost certain to increase further. 
Men continue to experience about two-thirds ofHCV-attributable hospital stays. 
Medicaid and Medicare continue to bear a substantial burden from HCV, with more than 
15% annual growth in hospital visits for people enrolled in these programs through 2004. 
Deaths associated with HCV-attributable hospital stays increased over the time period 
analyzed, and about 8% of these stays resulted in death. About 5% of the HCV-
attributable stays were for patients who also had a diagnosis ofHIV/AIDS. Analysis of 
the North Carolina Medicaid claims data shows that both the paid claims related to HCV 
diagnoses, and the number of clients with some diagnosis ofHCV, also grew during the 
2003-2005 time period. 
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Counting all discharges with any HCV diagnosis, HCV was associated with over 
$200 million in inpatient hospital charges in North Carolina in 2004 (2005 dollars). The 
North Carolina Medicaid system paid at least $32 million in 2005 for HCV-related 
claims, of which $25 million was for inpatient hospital visits. Counting only discharges 
with both HCV and liver-related conditions (very likely due to HCV), HCV was 
associated with at least $70 million in inpatient hospital charges statewide. If current 
trends continue, in 2006, there will be more than $100 million statewide in inpatient 
hospital charges directly attributable to HCV. Since inpatient hospital costs are only one 
of many direct and indirect economic cost components, the total economic cost of the 
disease in North Carolina is clearly even higher. The estimates of inpatient hospital 
charges presented here can probably be considered a bare-minimum or "lower bound" on 
the true direct medical costs associated with HCV. 
The results presented in this paper generally validate the work of previous 
researchers, who without exception predicted that HCV hospital stays, charges, and 
mortality would continue to grow at a national level. It appears that the economic impact 
ofHCV in North Carolina is currently following growth trends in the range of20% 
annual growth, mirroring the national HCV trends documented by earlier research. The 
rates of growth of hospital stays and charges may now be declining somewhat, but actual 
overall growth is still quite significant, as HCV infections acquired long ago continue to 
progress to serious liver disease in people aged roughly 35 to 64. Also, the burden borne 
by public funding (Medicaid and Medicare) is consistently more than 60% of the total 
economic burden. Finally, the continued aging of patients chronically infected with HCV 
decades ago is apparent in the recent shift of the burden from the younger (e.g., 35-44) 
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age groups, to the older ( 45-54 and 55-64) age groups. This shift obviously has serious 
implications for the costs to public programs, especially the Medicare system, over the 
next decade. 
There is no vaccine to prevent HCV. If and when a prophylactic vaccine becomes 
available, it will not help patients who acquired the infection long ago and who are now 
experiencing disease progression. Medical treatments and behavioral interventions are 
available to prevent or delay HCV disease progression. The preferred strategy for 
controlling the progression of the disease includes testing larger numbers of people in 
order to identify more of those infected, providing education, counseling, and referral for 
evaluation, and when appropriate, treating those who test positive with the best available 
medications. 
In North Carolina, there is clearly an opportunity to reduce costs and improve 
outcomes in the future if more HCV -positive patients are tested and identified early 
enough to take measures to prevent or delay disease progression. Even individuals who 
are not candidates for pharmaceutical treatment may need to be tested in order to know 
their disease status, obtain counseling and additional information, and prevent 
transmission to others. Unfortunately, very limited state and federal funding is available 
to support testing programs and other interventions to control chronic HCV disease. 
Additional research is also needed to help identify the regions of North Carolina that are 
most in need of resources and HCV programs, and to determine the local conditions and 
populations in which HCV screening would be most cost-effective and successful. These 
recommendations are described in more detail below. 
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8.2: Recommendations for Further Data Collection and Analysis. The 
analysis presented in this paper has shown that hospital stays and charges associated with 
HCV have grown very rapidly for the past several years in North Carolina. There are 
three additional areas of research that would further augment knowledge about the 
current burden ofHCV in North Carolina, and would help support the development of 
state policy and intervention programs. These recommended research topics follow. 
1) Obtain and analyze data on the utilization and treatment success rates of 
HCV medications in North Carolina. Unfortunately, medications for HCV are 
expensive, treatment success rates are relatively low, and side effects of treatment can be 
significant. Therefore, although HCV treatment has the potential to essentially cure the 
disease and prevent disease progression, it also has a significant impact on the burden of 
the disease. The number of patients who have been treated or are now being treated for 
HCV in North Carolina, the costs of the treatments, success rates, and the funding 
sources for treatment are all unknown. It is difficult to obtain state-level data on 
treatment utilization, costs, and outcomes from pharmaceutical firms and their data 
suppliers. Additional sources of this type of data should therefore be investigated. 
Sources of this type of information may include large health insurers in North Carolina 
such as Blue Cross Blue Shield, UNC Health Care, or other private insurers. HIP AA 
privacy regulations and other barriers may continue to limit the availability of this type of 
data. 
2) Conduct additional data analysis on the burden of HCV in North Carolina 
by region, e.g., zip code, county, or local health department catchment area. Due to 
space limitations as well as IRB rules, the analysis presented here was limited to 
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aggregate state-level results, rather than results by county or zip code. Further analysis of 
state Medicaid records and hospital outpatient and inpatient records would help identify 
the North Carolina regions and counties that have the largest numbers of hospital visits 
for HCV and the highest prevalence rates ofHCV, so that prevention, testing, and 
treatment resources can be directed towards these populations. Data to support this 
analysis may be available from Solucient or the Cecil B. Sheps Center at UNC. Ideally, 
the data must be obtained with the zip code included (the zip code was suppressed from 
the data used for this paper). Additional data to support regional-level research might be 
available from local health departments throughout the state. A telephone or e-mail 
survey oflocal health departments in North Carolina would be a good way to identify 
regions where HCV prevalence is believed to be relatively high and where resources are 
most sorely needed. 
3) Develop a comprehensive cost-effectiveness model of free or reduced-cost 
HCV testing/screening. Although numerous cost-effectiveness studies have been 
conducted to evaluate HCV treatment, 51 few studies have evaluated the complex 
economics ofHCV testing. Screening for HCV, if followed by appropriate education, 
counseling, and possibly treatment, is clearly cost-effective in specific high-prevalence 
populations, but no studies appear to exist that evaluate the conditions under which low-
cost HCV testing is cost-effective if offered in health departments or similar public 
settings. A cost-effectiveness study of public, reduced-fee testing could be developed 
using data specific to North Carolina (including the data reported here) and other 
published data. Cost-effectiveness could be evaluated from the perspective of the state 
budget, e.g., the state Medicaid system, or from the perspective of society as a whole. 
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Although the "societal perspective" is preferred in standard cost-effectiveness analysis, 52 
using the perspective of the state budget might best support efforts to obtain funding from 
state legislators and other policymakers. 
Published cost-effectiveness studies usually make numerous assumptions about 
key parameters, and use sensitivity analysis to assess which parameters have the greatest 
impact on the results. 52 In order to be useful for making decisions about providing 
regional HCV screening programs, a cost-effectiveness model ofHCV testing should be 
flexible with regard to assumptions about key parameters, including the prevalence of 
HCV in the population being tested and the success rates of HCV treatments. Since new 
treatments may be available in a few years for chronic HCV, a cost-effectiveness model 
should also consider the possibility of delaying treatment until treatment options improve, 
as has been recommended by earlier researchers. 53 
8.3: Recommendations for Policy Change. The additional data collection and 
analysis recommended above would help achieve the goals of further quantifYing the 
burden ofHCV in North Carolina, and identifying the regions and populations in North 
Carolina that are in greatest need ofHCV testing and other services. The magnitude and 
continued consistent growth of the HCV burden suggest that there is also an immediate 
need for testing programs and for educational and treatment interventions to prevent 
disease progression. Based on the results presented in this paper, three recommendations 
are given for North Carolina HCV policy change. 
1) HCV testing should be made more widely available to the North Carolina 
public at free or reduced cost. The people at greatest risk for chronic HCV disease in 
North Carolina and in other states are precisely the people who often have limited access 
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to health care, and therefore, to HCV testing and treatment. Results of previous CDC 
surveys have shown that compared with other states, North Carolina has less public 
capacity for HCV screening and follow-up care. Another survey presently underway (by 
NASTAD) will probably show that North Carolina is still behind most other states in 
providing HCV testing and other services. Currently North Carolina has only two 
locations where HCV testing is offered for free through public health departments. Data 
and evaluations from these "pilot" testing sites should be collected, analyzed, and used to 
inform the development of additional testing programs at other sites across the state, as 
soon as funding is available. 
2) Free or reduced-cost HCV testing programs should not be strictly limited 
to people who report risk factors for HCV. The stigmas associated with risk factors 
for HCV,such as current or former injection drug use, may be significant. Requiring 
clients to identify these risk factors may lead to missed opportunities to test people who 
should be tested. Also, ifHCV programs are implemented within existing HIV/STD 
infrastructure in local health departments, steps should be taken to make sure that HCV is 
accurately represented as a separate disease. Focusing HCV testing resources on the 
HIV-positive population will only identify a small proportion ofHCV-positive people, 
since only about 10% ofHCV-positive are HIV-co-infected. For these reasons, HCV 
screening programs should be designed and communicated so that they are as broad and 
inclusive as possible, while still reaching people likely to be at risk for HCV. Also, HCV 
screening programs should ideally include additional tests to rule out false positives in 
anti-HCV results, and RNA testing to determine whether a positive HCV antibody result 
indicates chronic or resolved infection, as recommended by CDC and other experts. 
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3) Develop a surveillance system and patient registry for chronic HCV. 
Chronic HCV is not yet reportable in North Carolina, and there is no registry system for 
the disease. A surveillance system for reporting chronic HCV would improve knowledge 
about the extent of the disease burden and the regions of the state that are most affected. 
Improved surveillance could also help reduce transmission and prevent new cases of 
HCV infection. In addition, available data (such as the hospital inpatient database 
analyzed for this paper) is based on hospital stays rather than patients; longitudinal 
analysis of disease progression and outcomes for HCV patients is currently not possible. 
A statewide HCV patient registry is needed to facilitate keeping track of newly identified 
chronic HCV patients, increase the likelihood that patients will receive appropriate care, 
treatment, and follow-up, and improve patient outcomes. 
In conclusion, there is an opportunity to control the growing burden ofHCV 
disease in North Carolina by conducting additional research and changing state policy. 
Immediate action is needed to secure resources toward implementing HCV programs in 
North Carolina, particularly programs such as free or low-cost HCV testing, improved 
HCV surveillance, and a patient registry. 
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Figure 1: CDC Recommendations for HCV Testing, 2006 
Recommendations for Testing Based on Risk for HCV Infection 
PERSONS RISK OF TESTING 
INFECTION RECOMMENDED? 
Injecting drug users High Yes 
Recipients of clotting 
factors made before 
1987 High Yes 
Hemodialysis patients Intermediate Yes 
Recipients of blood 
and/or solid organs 
before 1992 Intermediate Yes 
People with 
undiagnosed liver 
problems Intermediate Yes 
Infants born to After 12-18 mos. 
infected mothers Intermediate old 
Healthcarejpublic Only after known 
safety workers low exposure 
People having sex with 
multiple partners low No* 
People having sex with 
an infected steady 
partner low No* 
*Anyone who wants to get tested should ask their doctor. 
Source: Centers for Disease Control and Prevention, 
http://www.cdc.gov/ncidodldiseases/hepatitis/resource/PDFs/risk of infection.pdf 
(accessed September 13, 2006) 
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Table 1: Mortality Rates for Hepatitis C, North Carolina and United States, 1999-2003 
HCV Deaths and Death Rates 1999 
North Carolina HCV Deaths 78 
Age-adjusted Death Rate per 100,000 1.0 
United States HCV Deaths 3,763 
Age-adjusted Death Rate per 100,000 1.4 
% of US HCV Deaths in NC 2.1% 






















Table 2: Population Estimates, North Carolina vs. United 
States 
Estimate 
Estimated Population, 2005 
NC Population as % of U.S. Population 
%of Population, Female, 2004 
% of Population, < 5 years old, 2004 
% of Population, < 18 years old, 2004 
%of Population, age 65+, 2004 
% of Population, Black, 2004 
% of Population, White, 2004 




Estimated # of Prisoners 
# per 100,000 Population 
Estimated # living with HIV I AIDS 
# per 100,000 Population 
Sources: 
U.S. Census Bureau, State and County QuickFacts 


















U.S. Census 2005 American Community Survey (U.S.) 
Drug Enforcement Administration, 
www.dea.gov 


















Table 3: Liver Transplants in North Carolina and United States, 1996-2005 
Year 
Number of Transplants 1996 1997 1998 1999 2000 2001 
North Carolina 88 101 144 121 145 122 
United States 4082 4187 4516 4751 4995 5190 
NC% ofUS 2.2% 2.4% 3.2% 2.5% 2.9% 2.4% 
Total North Carolina, 1996-2005 
1,223 
Total United States, 1996-2005 
51,335 















Source: Organ Procurement and Transplantation Network, http://www.optn.org/latestData/rptData.asp (September 18, 2006) 
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Table 4: Growth Rates for North Carolina Hospital Inpatient Database Measures, All Diagnoses, 1996-2004 
Charges adjusted to 2005 dollars using U.S. Consumer Price Index for Medical Care. 
Measure CAGR% Average CAGR% 
1996-2004 Annual 2001-2004 
Growth Rate 
% 
Total Hospital I 2.2% 2.2% 1.6% 
Discharges 
Total Hospital Days I 0.6% 0.7% 1.4% 
Total Hospital 5.1% 5.2% 8.9% 
Charges (2005 $) 
Source: NC Hospital Inpatient Database, Solucient (1996-2004), courtesy ofSheps Center 
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Figure 2. 

















1996 1997 1998 1999 2000 2001 2002 2003 2004 
Year 
I ~Discharges .......,.. Charges I 
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Table 5: North Carolina Hospital Discharges with Any Diagnosis ofHCV, 1996-2004: Growth Rates 
Population Group Total %of CAGR Average CAGR% 
Discharges Group % 1996- Annual 2001-2004 
1996-2004 2004 GR% 
Total Discharges I 47411 wo% I 24.7% 25.0% 17.0% 
By Age Group 
0-24 464 1% 12.3% 17.2% 22.8% 
25-34 3209 7% 9.5% 10.0% 2.6% 
35-44 15908 34% 18.9% 19.5% 8.0% 
45-54 18424 39% 38.0% 38.5% 24.2% 
55-64 5137 11% 33.1% 33.4% 26.4% 
65+ 4269 9% 13.3% 13.8% 13.2% 
By Gender 
Male 29322 62% 25.7% 26.0% 17.6% 
Female 18088 38% 23.1% 23.5% 16.0% 
By Payer 
Medicaid 13141 28% 24.0% 24.2% 20.5% 
Medicare 15949 34% 24.5% 24.7% 19.7% 
Other I Unknown 18321 39% 25.5% 26.1% 12.4% 
Source: NC Hospital Inpatient Database, Solucient (1996-2004), courtesy ofSheps Center 
Records included in this table had at least one diagnosis ofHCV (070.41, 070.44, 070.51, 070.54) in at least 















All NC HCV-Related Discharges by Age Group 









Table 6: North Carolina Hospital Charges and Days with Any Diagnosis of HCV, 1996-2004 
All charges adjusted to 2005 dollars using U.S. Consumer Price Index for Medical Care. 
Year 
Hospital 1996 1997 1998 1999 2000 2001 2002 2003 2004 CAGR Avg CAGR 
Charges and % Annual % 
Days 1996- GR% 2001-2004 2004 
Total Charges I $32.5 $38.9 $54.5 $61.2 $84.2 $108.3 $136.5 $168.7 $204.5 25.8% 26.1% 23.6% 
($Million) 
Total Days I 12,928 14,450 19,057 24,000 31,040 38,590 43,929 52,348 61,277 21.5% 21.7% 16.7% Median $10,387 $10,079 $9,704 $8,669 $8,474 $9,079 $9,974 $10,330 $11,095 0.8% 1.0% 6.9% 
Charge/Stay ($) 
Mean I $19,046 $19,402 $19,672 $16,197 $17,141 $17,380 $18,815 $19,216 $20,509 0.9% 1.2% 5.7% 
Charge/Stay ($) 
Standard Error I $751 $788 $689 $455 $471 $371 $382 $348 $329 N/A N/A N/A 
Charge/Stay ($) 
Mean Days/Stay 7.6 7.2 6.9 6.4 6.3 6.2 6.1 6.0 6.1 -2.6% -2.5% -0.3% 
Source: NC Hospital Inpatient Database, Solucient (1996-2004), courtesy ofSheps Center. 
Records included in this table had at least one diagnosis ofHCV (070.41, 070.44, 070.51, 070.54) in at least one diagnosis code field. 
Note: The "N" values for the means and standard errors on charges per stay are the Total Discharges shown in Table A-2. 
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Table 7: North Carolina Hospital Discharges with both HCV and Liver-Related Diagnoses, 1996-2004: 
Growth Rates 
Population Group Total %of CAGR Avg CAGR% 
Discharges Group % Annual 2001-2004 
1996- GR% 1996-2004 2004 
Total Discharges I 17009 1oo% I 2o.2% 20.5% 12.9% 
By Age Group 
0-24 69 0% * * * 
25-34 556 3% -3.4% -1.5% -6.1% 
35-44 4843 28% 13.3% 14.0% 1.9% 
45-54 7456 44% 33.3% 34.2% 18.1% 
55-64 2153 13% 29.0% 29.5% 20.4% 
65+ 1932 11% 6.3% 7.4% 10.2% 
By Gender 
Male I 11227 66%122.1% 22.3% 14.5% 
Female 5782 34% 17.1% 17.7% 9.9% 
By Payer 
Medicaid 4909 29% 21.6% 22.0% 15.8% 
Medicare 5616 33% 18.5% 18.8% 16.5% 
Other I Unknown 6484 38% 20.9% 21.4% 7.9% 
Source: NC Hospital Inpatient Database, Solucient (1996-2004), courtesy ofSheps Center. 
Records included in this table had at least one diagnosis of HCV and at least one diagnosis of liver disease or a 
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Table 8: North Carolina Hospital Charges and Days, Patients with both HCV and Liver-Related 
Diagnoses, 1996-2004 
All charges adjusted to 2005 dollars using U.S. Consumer Price Index for Medical Care. 
Year 
Hospital Charges 1996 1997 1998 1999 2000 2001 2002 2003 2004 CAGR Average CAGR 
and Days % 1996- Annual %2001-
2004 GR% 2004 
Total Charges I $15.9 $18.1 $25.4 $24.9 $33.2 $42.6 $55.2 $61.4 $70.6 20.5% 21.2% 18.3% 
($Million) 
Total Days I 5,687 6,342 8,458 9,139 11,707 14,178 16,397 17,979 20,158 17.1% 17.4% 12.4% 
Median $10,608 $10,046 $10,207 $9,078 $9,016 $9,557 $10,907 $11,011 $11,783 1.3% 1.6% 7.2% 
Charge/Stay ($) 
Mean 1 $21,443 $20,877 $21,612 $17,442 $18,455 $18,959 $21,477 $20,845 $21,823 0.2% 0.6% 4.8% 
Charge/Stay ($) 
Standard Error I $1,447 $1,312 $1,165 $776 $834 $673 $782 $688 $621 N/A N/A N/A 
Charge/Stay ($) 
Mean Days/Stay 7.7 7.3 7.2 6.4 6.5 6.3 6.4 6.1 6.2 -2.6% -2.5% -0.4% 
Source: NC Hospital Inpatient Database, Solucient (1996-2004), courtesy ofSheps Center. 
Records included in this table had at least one diagnosis of HCV and at least one diagnosis of liver disease or a liver transplant (or, 
HCV as the primary diagnosis). 
Note: The "N" values for the means and standard errors on charges per stay are the Total Discharges shown in Table A-3. 
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Table 9: North Carolina Hospital Charges, Patients with both HCV and Liver-Related Diagnoses, 1996-2004 
By Age Group and Payer Status 
All charges adjusted to 2005 dollars using U.S. Consumer Price Index for Medical Care. 
Year 
Hospital 1996 1997 1998 1999 2000 2001 2002 2003 2004 CAGR% Average CAGR% 
Charges 1996- Annual 2001-
($Million) 2004 GR% 2004 I Total I $15.9 $18.1 $25.4 $24.9 $33.2 $42.6 $55.2 $61.4 $70.6 20.5% 21.2% 18.3% 
By Age 
Group 
0-24 $0.1 $0.0 $0.2 $0.1 $0.2 $0.7 $0.3 $0.3 $0.2 * * * 
25-34 $1.2 $0.8 $0.9 $0.8 $0.8 $1.0 $1.2 $1.4 $1.5 3.0% 4.9% 13.1% 
35-44 $6.5 $6.4 $9.1 $7.7 $11.3 $12.1 $14.7 $13.7 $14.4 10.6% 12.4% 6.1% 
45-54 $3.5 $6.4 $9.1 $9.8 $13.4 $20.2 $26.4 $31.3 $36.3 33.9% 35.6% 21.6% 
55-64 $1.6 $2.0 $3.3 $3.0 $4.1 $5.6 $7.7 $9.6 $13.2 30.3% 31.9% 32.7% 
65+ $3.0 $2.5 $2.9 $3.4 $3.3 $3.0 $4.8 $5.1 $4.9 6.4% 8.5% 17.6% 
By Payer 
Medicaid $4.2 $4.6 $6.3 $6.4 $8.3 $11.7 $17.1 $16.4 $20.6 22.0% 23.3% 20.6% 
Medicare $4.9 $5.7 $8.2 $8.4 $10.2 $11.2 $17.3 $20.3 $23.6 21.7% 22.8% 28.3% 
Other or $4.8 $5.7 $8.2 $7.9 $11.8 $16.7 $18.4 $22.7 $25.4 23.1% 24.4% 15.0% 
Unknown 
*Too few observations for calculations to be meaningful; no apparent trend 
Source: NC Hospital Inpatient Database, Solucient (I 996-2004), courtesy of Sheps Center 
Records included in this table had at least one diagnosis of HCV and at least one diagnosis of liver disease or a liver transplant (or, 
HCV as the primary diagnosis). 
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Table 10: North Carolina Hospital Stays resulting in Death, Patients with both HCV and Liver-Related Diagnoses, 1996-2004 
By Age Group 
Year 
Stays Resulting in 1996 1997 1998 1999 2000 2001 2002 2003 2004 CAGR% Average CAGR% 
Death 1996- Annual 2001-
2004 GR% 2004 
Total Deaths 65 75 95 122 128 176 221 198 252 18.5% 19.4% 12.7% 
Deaths, % of All 8.8% 8.7% 8.1% 8.5% 7.1% 7.8% 8.6% 6.7% 7.8% -1.5% -0.6% -0.1% 
Stays 
# Deaths By Age Group 
0-24 1 0 2 0 1 0 0 1 0 * * * 
25-34 3 7 1 4 0 4 2 1 4 * * * 
35-44 18 18 26 38 33 42 44 35 34 8.3% 10.8% -6.8% 
45-54 13 22 29 42 53 77 110 97 125 32.7% 34.7% 17.5% 
55-64 10 10 13 10 21 28 27 34 56 24.0% 29.7% 26.0% 
65+ 20 18 24 28 20 25 38 30 33 6.5% 9.7% 9.7% 
*Too few observations for calculations to be meaningful; no apparent trend 
Source: NC Hospital Inpatient Database, Solucient (1996-2004), courtesy ofSheps 
Center 
Records included in this table had at least one diagnosis of HCV and at least one diagnosis of liver disease or a liver 
transplant (or, HCV as the primary diagnosis), and a confirmed outcome of death, in the hospital or elsewhere. 
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Table 11: North Carolina Hospital Stays for Patients with HIV/AIDS and both HCV and Liver-Related Diagnoses, 1996-2004 
By Age Group 
Year 
Stays for 1996 1997 1998 1999 2000 2001 2002 2003 2004 CAGR% Average CAGR% 
HIV/AIDS and 1996- Annual 2001-
HCV -Coinfected 2004 GR% 2004 
Total Coinfected I 53 61 85 80 88 148 140 147 170 15.7% 17.7% 4.7% 
Stays 
Coinfected Stays, I 7.2% 7.0% 7.2% 5.6% 4.9% 6.6% 5.5% 5.0% 5.3% -3.8% -2.5% -7.2% 
% ofAllHCV 
Stays 
Coinfected Stays by Age Group 
0-24 0 0 2 0 1 1 0 7 6 
25-34 10 13 6 2 2 10 5 6 5 
35-44 27 29 42 44 42 68 57 52 52 
45-54 11 16 31 28 20 61 63 67 78 
55-64 5 3 4 6 22 8 14 13 26 
65+ 0 0 0 0 1 0 1 2 3 
Source: NC Hospital Inpatient Database, Solucient (1996-2004), courtesy ofSheps Center 
Records included in this table had at least one diagnosis of HCV, at least one diagnosis of liver disease or a liver transplant, 
(or, HCV as the primary diagnosis), and a diagnosis ofHIV-J/AIDS, HIV-2, or HIV-positive status. 
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Table 12: North Carolina Medicaid Claims Paid, 2003-2005 
NOTE: All claims had some diagnosis of HCV. 
Because some claim types do not include diagnosis codes, not all claims associated with HCV are 
represented. 
All charges adjusted to 2005 dollars using U.S. Consumer Price Index for Medical Care. 
Claims Paid, 2005 $Million 
Total Paid 
Medical Office Visits, Equipment 
Outpatient Clinic or Hospital Visits 







































Table 13: Number oflndividual Medicaid Recipients with Any Diagnosis of HCV, 
by Subgroups 
(Counts of Known HCV-Diagnosed Medicaid Recipients) 
NOTE: All recipients had a claim with some diagnosis ofHCV. 
Because some claim types do not include diagnosis codes, not all recipients are included. 
Number of 




Growth Rate%, Year on Year 








By Gender # 
Male 3278 
Female 3562 































# % # % 
48 (1) 76 (I) 
144 (2) 166 (2) 
491 (6) 479 (6) 
2513 (32) 2362 (29) 
3360 (43) 3719 (45) 
900 (12) 1139 (14) 
308 (4) 286 (3) 
# % # % 
3680 (47) 3889 (47) 
4084 (53) 4338 (53) 
# % # % 
62 (I) 62 (1) 
2792 (36) 3072 (37) 
47 (1) 20 () 
108 (1) 134 (2) 
580 (7) 186 (2) 
33 () 291 (4) 
4142 (53) 4462 (54) 
.. Source: J. T1mothy Whttmtre, North Caro1ma State Center for Health Stattsttcs 
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APPENDIX: SUPPLEMENTAL TABLES 
6S 
Table A-1: ICD-9-CM Diagnosis Codes Used to Select Database Records 
ICD-9-CM Definition Code# Years 
Acnte or unspecified Hepatitis C with hepatic coma 070.41 All 
Acute or unspecified Hepatitis C, without hepatic coma 070.51 All 
Chronic Hepatitis C, with hepatic coma 070.44 All 
Chronic Hepatitis C, without hepatic coma 070.54 All 
Unspecified viral Hepatitis C, without hepatic coma 070.70 2005 only 
Unspecified viral Hepatitis C, with hepatic coma 070.71 2005 only 
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Table A-2: North Carolina Hospital Discharges for Patients with Any Diagnosis of HCV, 1996-2004 
Year 
Number of 1996 1997 1998 1999 2000 2001 2002 2003 2004 CAGR Avg CAGR 
Hospital % 1996- Annual % 
Discharges 2004 GR% 2001-2004 
Total I 1707 2007 2772 3777 4910 6230 7257 8780 9971 24.7% 25.0% 17.0% 
Discharges 
By Age Group 
0-24 30 24 41 60 60 41 59 73 76 12.3% 17.2% 22.8% 
25-34 232 241 249 273 369 443 445 479 478 9.5% 10.0% 2.6% 
35-44 690 782 1090 1502 1880 2181 2435 2597 2751 18.9% 19.5% 8.0% 
45-54 351 531 826 1167 1699 2403 2953 3890 4604 38.0% 38.5% 24.2% 
55-64 136 168 239 349 452 661 779 1017 1336 33.1% 33.4% 26.4% 
65+ 268 261 327 426 450 501 586 724 726 13.3% 13.8% 13.2% 
By Gender 
Male I 995 1240 1707 2332 3014 3823 4491 5504 6216 25.7% 26.0% 17.6% 
Female 712 767 1065 1444 1896 2407 2766 3276 3755 23.1% 23.5% 16.0% 
By Payer 
Medicaid 511 571 779 981 1300 1630 2048 2472 2849 24.0% 24.2% 20.5% 
Medicare 594 706 915 1297 1614 1997 2398 3002 3426 24.5% 24.7% 19.7% 
Other or 602 730 1078 1499 1996 2603 2811 3306 3696 25.5% 26.1% 12.4% 
Unknown 
Source: NC Hospital Inpatient Database. Solucient (1996-2004), courtesy of Sheps 
Center 
Records included in this table had at least one diagnosis ofHCV (ICD-9-CM 070.41, 070.44, 070.51, 070.54) 
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Table A-3: North Carolina Hospital Discharges, Patients with both HCV and Liver-Related Diagnoses, 1996-2004 
Year 
Number of 1996 1997 1998 1999 2000 2001 2002 2003 2004 CAGR Average CAGR 
Hospital % 1996- Annual % 
Discharges 2004 GR% 2001-2004 (Stays) 
Total Discharges I 741 867 1177 1428 1798 2249 2568 2947 3234 20.2% 20.5% 12.9% 
By Age Group 
0-24 6 1 11 5 12 6 6 11 11 * * * 
25-34 70 58 44 56 62 64 73 76 53 -3.4% -1.5% -6.1% 
35-44 252 320 416 494 614 647 730 686 684 13.3% 14.0% 1.9% 
45-54 169 262 399 519 696 1021 1183 1525 1682 33.3% 34.2% 18.1% 
55-64 67 88 120 159 203 295 320 386 515 29.0% 29.5% 20.4% 
65+ 177 138 187 195 211 216 256 263 289 6.3% 7.4% 10.2% 
By Gender 
Male 440 566 776 946 1201 1447 1683 1998 2170 22.1% 22.3% 14.5% 
Female 301 301 401 482 597 802 885 949 1064 17.1% 17.7% 9.9% 
%Male 59.4% 65.3% 65.9% 66.2% 66.8% 64.3% 65.5% 67.8% 67.1% 
By Payer 
Medicaid 205 222 308 398 486 629 784 900 977 21.6% 22.0% 15.8% 
Medicare 276 313 431 477 573 678 846 950 1072 18.5% 18.8% 16.5% 
Other or 260 332 438 553 739 942 938 1097 1185 20.9% 21.4% 7.9% 
Unknown 
* Observations too small for calculations to be meaningful; no apparent trend 
Source: NC Hospital Inpatient Database, Solucient (1996-2004), Sheps Center 
Records included in this table had at least one diagnosis of HCV and at least one diagnosis of liver disease or a liver transplant 
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